What is Samter's triad (aspirin‑exacerbated respiratory disease) and what are the recommended management strategies?

Samter's Triad (Aspirin-Exacerbated Respiratory Disease)

Samter's triad, now termed Aspirin-Exacerbated Respiratory Disease (AERD), is a clinical syndrome characterized by the triad of chronic rhinosinusitis with nasal polyposis (CRSwNP), asthma, and respiratory reactions to aspirin and other NSAIDs that inhibit cyclooxygenase-1. 1, 2

Definition and Clinical Features

AERD affects approximately 0.3-0.9% of the general population and up to 7-15% of patients with asthma or CRSwNP 3, 4. The key distinguishing feature is that patients develop acute upper and/or lower respiratory symptoms within 30-180 minutes after ingesting NSAIDs like aspirin or ibuprofen 3. Even without NSAID exposure, these patients typically experience more severe upper and lower respiratory disease compared to patients with CRSwNP or asthma alone 5, 6.

The underlying pathophysiology involves:

• Systemic dysregulation of arachidonic acid metabolism
• Aberrant type 2 inflammatory response with eosinophilic inflammation
• Disruption of respiratory epithelial barrier integrity
• Imbalance between fibrin formation and degradation in nasal polyps 3

Diagnosis

Diagnosis is primarily clinical, based on the presence of all three components of the triad plus a convincing history of respiratory reactions to NSAIDs. 1 When the history is unclear, an aspirin challenge test can confirm the diagnosis 6, 4. The diagnosis of CRSwNP must be confirmed by direct visualization of nasal polyps with nasal endoscopy 1.

Management Strategies

Medical Management

The 2023 Joint Task Force guidelines provide the most current evidence-based approach 1:

1. Intranasal Corticosteroids (INCS)

• Suggested as first-line therapy for all patients with CRSwNP, including AERD (conditional recommendation) 1
• Multiple delivery methods available: sprays, rinses/irrigations, exhalation delivery systems, drops
• Must be used daily for effectiveness

2. Biologics

• Target type 2 inflammation pathways
• FDA-approved options include:
  • Dupilumab (anti-IL-4/IL-13)
  • Mepolizumab (anti-IL-5)
  • Omalizumab (anti-IgE)
• Particularly promising for patients with severe disease refractory to conventional therapy 5, 7
• The 2025 AAO-HNS guideline now recognizes biologics as an important treatment option 2

3. Aspirin Therapy After Desensitization (ATAD)

• The guideline panel suggests ATAD rather than no ATAD for patients with AERD (conditional recommendation based on moderate certainty of evidence). 1
• This is a two-part process:
  • Desensitization phase: Gradual exposure to increasing aspirin doses (up to 325 mg) over 1-3 days under medical supervision
  • Maintenance phase: Daily aspirin therapy at 650-1300 mg per day
• Critical caveat: The desensitization itself provides no clinical benefit—only the subsequent daily aspirin therapy does 1
• Major safety consideration: Aspirin must be taken every single day; missing doses for >2 days requires re-evaluation and possible repeat desensitization 1

Balance of benefits vs. harms for ATAD:

• Benefits: Improvement in disease-specific quality of life and nasal symptoms
• Harms: Gastrointestinal side effects and increased bleeding risk (GI or intracranial)
• Contraindications/high-risk conditions: Poorly controlled asthma, conditions increasing bleeding risk (age, male sex, smoking, diabetes, hypertension, systemic corticosteroid use, lower BMI) 1

4. Anti-leukotrienes

• Can be considered as part of multimodal therapy 1

Surgical Management

Endoscopic sinus surgery is frequently required and, when followed by continued medical management (with or without ATAD), often improves both symptoms and objective disease measures 5, 4.

Treatment Algorithm

For newly diagnosed AERD patients:

1. Confirm diagnosis with nasal endoscopy showing polyps and history of NSAID respiratory reactions
2. Initiate INCS as baseline therapy
3. Optimize asthma control before considering other interventions
4. Consider surgical intervention if medical therapy inadequate
5. After surgery, choose between:
   • ATAD if patient values symptom improvement over bleeding/GI risks AND has no contraindications
   • Biologics if patient has contraindications to ATAD or prefers to avoid aspirin risks
   • Combination therapy may be considered in severe cases

Shared decision-making is essential because the balance between benefits and harms of ATAD is close, and different patients will weigh these factors differently 1. Those who prioritize quality of life improvement may favor ATAD, while those concerned about bleeding or GI complications may prefer biologics or surgery alone with continued INCS.

Critical Implementation Points

• ATAD requires specialized training and a setting where reactions can be managed 1
• Patients need extensive education about daily aspirin adherence and what to do if procedures require temporary cessation 1
• Long-term monitoring for adverse effects of aspirin is mandatory 1
• AERD is now recognized as a chronic condition that modifies CRS management 2